University of Erlangen–Nuremberg is a public research university in the cities of Erlangen and Nuremberg in Bavaria, Germany. The name Friedrich–Alexander comes from the university's first founder Friedrich, Margrave of Brandenburg-Bayreuth, and its benefactor Alexander, Margrave of Brandenburg-Ansbach.

During the past decade, University of Erlangen conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 11 clinical trials were completed, i.e. on average, 47.8% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Erlangen" #1 sponsor was "University of Erlangen-Nürnberg Medical School" with 14 trials, followed by "Vertex Pharmaceuticals Incorporated" with 7 trials sponsored, "University of Erlangen-Nürnberg" with 3 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored and "Celgene" with 2 trials sponsored. Other sponsors include 33 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Erlangen" #1 collaborator was "German Federal Ministry of Education and Research" with 3 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "ORION Clinical Services" with 2 trials as a collaborator, "ABX CRO" with 1 trials as a collaborator and "Aktion Multiple Sklerose Erkrankter, Landesverband der DMSG in Baden-Württemberg (AMSEL) e.V." with 1 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "University of Erlangen" are "Cystic Fibrosis" (7 trials), "Ulcerative Colitis" (4 trials), "Breast Cancer" (3 trials), "Crohn´s Disease" (3 trials) and "Hypertension" (3 trials). Many other conditions were trialed in "University of Erlangen" in a lesser frequency.

Most popular intervention types in "University of Erlangen" are "Drug" (36 trials), "Device" (13 trials), "Other" (8 trials), "Behavioral" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "IVA" (7 trials), "ELX/TEZ/IVA" (4 trials), "Placebo (matched to ELX/TEZ/IVA)" (3 trials) and "Placebo (matched to IVA)" (3 trials). Other intervention names were less common.

The vast majority of trials in "University of Erlangen" are 59 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "University of Erlangen". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 46 completed trials in University of Erlangen, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in University of Erlangen, 4 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 11 trials that are defined as “Not Applicable".

University of Erlangen has several departments that took part in Clinical trials: "Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg" - 18 trials, "Department of Medicine I, University of Erlangen-Nuremberg" - 4 trials